|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The nonsynonymous SNP, rs700519 (Arg264Cys), located in haplotype block 4, was also associated with breast cancer survival.
|
17119036 |
2006 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The results suggest that the CYP19 Arg(264)Cys polymorphism modifies breast cancer</span> risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the CYP1B1 Leu(432)Val polymorphism appears to play no role here.
|
12618873 |
2003 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
|
20133979 |
2010 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
|
19469636 |
2009 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
|
15298966 |
2004 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Aromatase and breast cancer: W39R, an inactive protein.
|
11916629 |
2002 |
|
rs4775936
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We discuss the implications of this association for links between D<sub>r-l</sub> and rs4775936 and prenatal sex steroids and for susceptibility to breast cancer.
|
30986648 |
2019 |
|
rs700518
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A reduced risk of a breast cancer event for tamoxifen-treated patients with rs700518 variants was observed (BCFI CC/TC vs. TT: HR 0.53, 95 % CI 0.34-0.82, interaction P = 0.08), but not observed for letrozole-treated patients.
|
25935582 |
2015 |
|
rs700518
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
|
26049585 |
2015 |
|
rs700518
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG 1.36, 95 % CI 1.11-1.67 and rs11856927, ORGG 1.35, 95 % CI 1.05-1.72.
|
25088806 |
2014 |
|
rs4775936
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
rs4775936
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively].
|
19064562 |
2008 |
|
rs1008805
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, the homozygous minor allele (GG) of <i>CYP19A1</i> rs1008805 was identified to be significantly associated with an inferior clinical outcome of hormone therapy in postmenopausal hormone receptor-positive patients with early breast cancer.
|
29113261 |
2017 |
|
rs1008805
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggest that premenopausal women carrying the G allele at CYP19 rs1008805 have increased risk of breast cancer.
|
17975727 |
2008 |
|
rs7176005
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The CYP19A1 SNP rs7176005 (p < 0.0045) and the CYP1A2 SNP rs762551 (p = 0.004) were significantly associated with BC risk.
|
31477036 |
2019 |
|
rs774053181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In summary, the BRCA1 Cys39Gly</span> and CYP17A1 -34T>C genetic variations were associated with breast cancer risk.
|
29510000 |
2018 |
|
rs3751591
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP19A1/rs3751591 was both associated with SHBG levels (P = 0.03) and with risk of BC (Incidence Rate Ratio = 2.12; 95 % Confidence Interval: 1.02-4.43) such that homozygous variant allele carriers had increased levels of serum SHBG and were at increased risk of BC.
|
27102200 |
2016 |
|
rs11856927
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG 1.36, 95 % CI 1.11-1.67 and rs11856927, ORGG 1.35, 95 % CI 1.05-1.72.
|
25088806 |
2014 |
|
rs1413421847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
|
19469636 |
2009 |
|
rs1004982
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively].
|
19064562 |
2008 |
|
rs28566535
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively].
|
19064562 |
2008 |
|
rs730154
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no significant association between rs730154 and breast cancer, regardless of menopausal status.
|
17975727 |
2008 |
|
rs936306
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The risk of breast cancer with (but not without) proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982 (C), rs28566535 (C), rs936306 (T), and rs4775936 (C) relative to those homozygous for the major allele [age-adjusted odds ratios (95% confidence intervals), 2.19 (1.24-3.85), 2.20 (1.27-3.82), 1.94 (1.13-3.30), and 1.95 (1.07-3.58), respectively].
|
19064562 |
2008 |